Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines

NCT00478816 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Prophylaxis of Avian Influenza Vaccine

Interventions

BIOLOGICAL: Fluad H5N1 Pandemic Influenza Vaccine

Sponsor

Novartis Vaccines